RxDoctor Payments DataLook up a doctor →

Masoom Kandahari, MD

Medical Oncology · Woodbridge, VANPI 1467448100

Payments from drug & device makers

$35,106in general payments, 2019–2025

Across 809 payments — averaging $43.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$5K
  • Rigel Pharmaceuticals, Inc.$4K
  • Acceleron Pharma, Inc.$3K
  • Johnson & Johnson$3K
  • Bristol Myers Squibb$3K
  • Novartis$2K
  • plus $16K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)52$4,573
Rigel Pharmaceuticals, Inc.10$3,846
Acceleron Pharma, Inc.3$3,290
Johnson & Johnson(2 entities)95$2,626
Bristol Myers Squibb44$2,620
Novartis49$1,710
CTI Biopharma Corp.2$1,527
Coherus Oncology, Inc.6$1,231
E.r. Squibb & Sons, L.L.C.46$1,044
Pfizer48$1,005
Genentech USA, Inc.23$790
Merck38$693
Amgen18$688
Sanofi21$622
Eisai Inc.20$598
Seagen Inc.24$526
Bayer17$523
Daiichi Sankyo Inc.18$507
Takeda Pharmaceuticals U.S.A., Inc.14$436
Lilly USA, LLC24$392
Pharmacyclics LLC, An Abbvie Company21$392
Karyopharm Therapeutics Inc.12$359
AbbVie10$320
Exelixis Inc.10$314
Sobi, Inc9$293
Gilead(2 entities)11$214
AVEO Pharmaceuticals, Inc.6$206
Taiho Oncology, Inc.9$204
Foundation Medicine, Inc.6$204
Incyte Corporation10$204
Array Biopharma Inc9$201
Puma Biotechnology, Inc.9$195
Global Blood Therapeutics, Inc.10$183
Beigene USA, Inc.7$169
Regeneron Healthcare Solutions, Inc.7$164
ASD Specialty Healthcare, LLC1$152
EMD Serono, Inc.6$133
Ipsen Biopharmaceuticals, Inc5$131
Tersera Therapeutics LLC5$127
TG Therapeutics, Inc.2$109
Astellas Pharma US Inc5$102
EUSA Pharma (US) LLC5$84
Lexicon Pharmaceuticals, Inc.3$82
Boehringer Ingelheim3$77
Epizyme, Inc.3$75
ADC Therapeutics America, Inc.3$73
Jazz Pharmaceuticals Inc.2$64
Heron Therapeutics, Inc.2$63
Blueprint Medicines Corporation3$61
GE HealthCare2$59
Clovis Oncology, Inc.3$55
Geron Corporation2$53
Pharmaessentia USA Corporation2$52
Sun Pharmaceutical Industries Inc.3$52
Myriad Genetic Laboratories, Inc.2$52
Beone Medicines USA, Inc.2$52
Pharmacosmos Therapeutics Inc.3$49
G1 Therapeutics, Inc.2$46
Servier Pharmaceuticals LLC2$44
Helsinn Therapeutics (U.S.), Inc.2$40

How this compares

$35,106 in reported general payments places this provider in the 55th percentile of 95 medical oncology providers in Virginia.

See all medical oncology providers in Virginia →

Medicare billing

Part B allowed, 2024
$18,835
Medicare patients
37
Services billed
1,896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Woodbridge

See the full list for Virginia →

Where these figures come from

Is this you, or does something look wrong? →